185147-20-0 Usage
Molecular Structure
Consists of a furanone ring attached to various functional groups.
Explanation
The compound has a complex molecular structure with a furanone ring as the central core, which is connected to multiple functional groups.
Explanation
These groups are attached to the furanone ring, contributing to the compound's unique properties and potential applications.
Explanation
Due to its unique structure and properties, the compound may have uses in creating new drugs or synthesizing other organic compounds.
Explanation
While the compound has potential applications, more research is needed to explore its properties, benefits, and any possible risks associated with its use.
Functional Groups
4-fluorophenyl, hydroxy, methyl, and sulfonyl phenyl groups.
Potential Applications
Pharmaceutical and organic synthesis fields.
Need for Further Research
To fully understand its potential uses and risks.
Check Digit Verification of cas no
The CAS Registry Mumber 185147-20-0 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,8,5,1,4 and 7 respectively; the second part has 2 digits, 2 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 185147-20:
(8*1)+(7*8)+(6*5)+(5*1)+(4*4)+(3*7)+(2*2)+(1*0)=140
140 % 10 = 0
So 185147-20-0 is a valid CAS Registry Number.
185147-20-0Relevant academic research and scientific papers
Black, W. Cameron,Brideau, Christine,Chan, Chi-Chung,Charleson, Stella,Cromlish, Wanda,Gordon, Robert,Grimm, Erich L.,Hughes, Gregory,Leger, Serge,Li, Chun-Sing,Riendeau, Denis,Therien, Michel,Wang, Zhaoyin,Xu, Li-Jing,Prasit, Petpiboon
, p. 1195 - 1198 (2003)
The introduction of a hydroxyl group into the 5-position of the diaryl furanone system provides highly selective inhibitors of cyclooxygenase-2. These molecules can be converted into their sodium salts which are water soluble, facilitating intravenous formulation. These salts show excellent potency in rat models of pain, fever and inflammation.
Diaryl-5-oxygenated-2-(5H) -furanones as COX-2 inhibitors
-
, (2008/06/13)
The invention encompasses the novel compound of Formula I as well as a method of treating cyclooxygenase-2 mediated diseases comprising administration to a patient in need of such treatment of a non-toxic therapeutically effective amount of a compound of Formula I. STR1 The invention also encompasses certain pharmaceutical compositions for treatment of cyclooxygenase-2 mediated diseases comprising compounds of Formula I.
